American Medical Association (AMA), 214, 240, 245

American Society for Histocompatibility and Immunogenetics, 121

American Society of Human Genetics (ASHG), 23, 25, 50, 74, 79, 121, 204, 218, 223-224, 228, 264, 291

informed consent guidelines, 14, 141, 172

Americans with Disabilities Act (ADA), 24, 272-273, 281, 282

Amniocentesis, 34, 35, 46, 73, 76, 78, 81, 83

Amyotrophic lateral sclerosis, 86

Analytic sensitivity of tests, 37, 139

Anencephaly, 79

Aneuploidy, 36

Animal models, 31

Anticipation, 63

Anxiety, 83, 104, 151

Appropriateness of tests, 9, 25, 27, 49-50

Asian and Pacific Islanders, 159

Association of American Medical Colleges (AAMC), 218

Association of Cytogenetic Technologists (ACT), 215-216

Association of Professors of Gynecology and Obstetrics, 220

Autonomy issues, 3, 14, 21, 23, 52-53, 54, 85, 149, 154, 160, 162, 171, 189, 247, 248-249, 259-260, 274-275

in multiplex testing, 27, 259, 275-276

reproductive decisions, 15, 19, 53, 103, 155-156

Autosomal dominant disorders, 61, 88, 91

Autosomal recessive disorders, 7, 61

carrier screening, 6, 7, 35, 70-74, 102

newborn screening, 6, 67

B

Behavioral modification, 45, 169

Biochemical genetics and analysis, 12, 59, 63, 75, 122, 138

carrier testing, 71

and false diagnoses, 66

Biological Sciences Curriculum Study (BSCS), 191

Biotinidase deficiency

screening programs, 5, 68-69

Birth defects, 34, 45-46, 75, 79

Blindness, 62, 63

Blood samples, 34

Breast cancer, 92, 93, 177

British Medical Association, 86

C

California, 120, 124, 168, 215

newborn and MSAFP screening, 120, 124, 168

sickle cell aide training, 215

Canadian College of Medical Genetics, 215

Canadian Royal Commission on New Reproductive Technologies, 86

Cancer, 1, 8, 29, 34, 63

predictive tests, 9, 36, 45, 87, 92-94, 96-97, 106, 107, 177, 238

Cardiovascular diseases, see Coronary artery disease;

Heart disease;

Hypertension (high blood pressure)

Carrier status, 2, 6-7, 23, 24, 37, 61, 70-74, 101-102, 148

counseling, 7, 101, 102, 163-166, 175-176

discovery by prenatal diagnosis, 27, 295

minors screened for, 7, 10, 102

and newborn screening, 6, 67, 70, 100, 162-163, 174-175

and prenatal testing, 7, 73, 75, 103, 176

Centers for Disease Control and Prevention (CDC), 124, 125, 291

lab proficiency testing programs, 12, 42, 121, 123, 133, 138

Central laboratories, 47, 48, 126-127, 299

for rare disorder testing, 12, 48, 127, 138

Certification and licensing

of laboratories, 11, 118, 124-126, 137

for rare disorder testing, 12, 127, 138

of specialists, 206, 207, 208, 2 13-216

Chevra Dor Yeshorim Program, 43



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement